SCHEMBL18306342

SCHEMBL18306342

Cc1cnc(-c2ccccc2F)c(-c2ccc(N)c(C=N)c2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.40
▸ MAP4K4 O95819 1/20 0.38
▸ FEN1 P39748 8/20 0.38
▸ ALOX5AP P20292 7/20 0.38
▸ BACE1 P56817 1/20 0.37
▸ FGFR1 P11362 1/20 0.36
▸ FGFR2 P21802 1/20 0.36
▸ FGFR3 P22607 1/20 0.36
▸ GABRG2 P18507 1/20 0.36
▸ GABRB3 P28472 1/20 0.36
▸ GABRA5 P31644 1/20 0.36
▸ GABRA3 P34903 1/20 0.36
▸ DHODH Q02127 2/20 0.35
▸ ADORA2A P29274 1/20 0.34
▸ ADORA1 P30542 1/20 0.34
▸ MAPK14 Q16539 2/20 0.34
▸ HTR5A P47898 1/20 0.33
▸ PDK2 Q15119 1/20 0.33
▸ LCK P06239 1/20 0.33
▸ KDR P35968 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18306300 0.85 USP7 (0.34) KMT2AFEN1ALOX5AP
SCHEMBL18306348 0.84 RPS6KA3 (0.37) MAP4K4FEN1ALOX5APFGFR1MAPK14
SCHEMBL18306447 0.84 KDM4E (0.40) MAP4K4FEN1ALOX5APBACE1FGFR1
SCHEMBL18306366 0.83 FYN (0.36) MAP4K4ADORA2AADORA1
SCHEMBL18306343 0.83 ABL1 (0.36) KMT2AFEN1ALOX5APBACE1FGFR1
SCHEMBL18306341 0.81 ADORA1 (0.42) KMT2AMAP4K4FGFR1ADORA2AADORA1
SCHEMBL18306344 0.74 MAP4K4 (0.37) MAP4K4FEN1ALOX5APFGFR1LCK
SCHEMBL18306367 0.74 AURKA (0.37) MAP4K4FEN1ALOX5APFGFR1GABRG2
SCHEMBL18306345 0.74 PTGS2 (0.39) MAP4K4FEN1ALOX5APFGFR1MAPK14
SCHEMBL18306302 0.73 MAP4K4 (0.44) MAP4K4FEN1ALOX5APBACE1GABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170342048-A1 GDF-8 Inhibitors MIDCAP FINANCIAL TRUST 2017-11-30 — — US disclosed
US-9518040-B2 GDF-8 inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2016-12-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170342048-A1 GDF-8 Inhibitors MSTN, MYOF, CXCL8 KMT2A 4190/4885MAP4K4 2844/4885FEN1 1544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback